SEC Form 4 · accession 0001209191-19-004894
Bionano Genomics, Inc. · BNGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Borodkin
Officer — Chief Operating Officer
Period of report
Jan 18, 2019
Accepted (ET)
Jan 22, 2019 · 9:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411690
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 18, 2019 | M | 6,000 | $1.30 | A | 6,815 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.30 | Jan 18, 2019 | M | 6,000 | D | — | Feb 6, 2027 | Common Stock | 6,000 | 28,219 | D |
Explanation of responses
- F125% of the shares vested on February 7, 2017, and the remaining shares vest in 12 equal quarterly installments thereafter.